Ocrelizumab for Psychosis by Autoimmunity

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-01

Study Completion Date

2025-10-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Some people who have what doctors currently call schizophrenia or bipolar disease may actually have a brain disease caused by auto-antibodies. Auto-antibodies are produced when the normal defense mechanism of the body goes wrong and begins to attack the body, similar to "friendly fire." Auto-antibodies attack brain receptors and then the person who has this problem begins to have hallucinations and other manifestations of schizophrenia, like feeling that people can see what they are thinking and also feeling that other people do not like them. If this disease is caused by auto-antibodies, typically the person is well until they are 15 years of age or older, but seldom older than 35 years. Then, in a matter of a few months they begin to have hallucinations and the other symptoms. Doctors still do not know whether some people with schizophrenia or bipolar disease have auto-antibodies attacking their brain. For this reason, in this study some of these patients will receive a treatment that suppresses the auto-antibodies and their symptoms after treatment will be compared with the symptoms of a group of similar patients who are given a preparation that looks like the real treatment, but it is not.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Immunotherapy in Autoantibody Positive Psychosis

NCT02449746

Schizophrenia Psychosis Auto Immune Disorders

COMPLETED NA

Tocilizumab in Schizophrenia

NCT02874573

Schizophrenia Psychotic Disorders

UNKNOWN PHASE1

Neuroplasticity in TBI and Schizophrenia

NCT03995368

Schizophrenia Traumatic Brain Injury

COMPLETED NA

Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

NCT05184335

Schizophrenia

RECRUITING PHASE3

Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia

NCT04822883

Cognitive Impairment Schizophrenia

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizo-Affective Type of Psychosis Schizophrenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized placebo-controlled therapeutic trial

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ocrelizumab

Two doses of 300 mg of ocrelizumab will be administered as an intravenous infusion two weeks apart.

Group Type ACTIVE_COMPARATOR

Psychosis and cognitive assessments

Intervention Type BEHAVIORAL

Administration of MINI, PANSS and Quality of Living scales

Physical and neuro-cognitive evaluations

Intervention Type BEHAVIORAL

Physical, neurological and cognitive evaluations.

Safety labs and electrocardiogram

Intervention Type DIAGNOSTIC_TEST

Metabolic panel, CBC and differential, urinalysis, ECG, recreational drugs. CD19+ B-cell count.

Ocrelizumab infusion

Intervention Type BIOLOGICAL

Two IV infusions of 300 mg of ocrelizumab 2 weeks apart

Placebo

Two placebo intravenous infusions will be administered two weeks apart.

Group Type PLACEBO_COMPARATOR

Psychosis and cognitive assessments

Intervention Type BEHAVIORAL

Administration of MINI, PANSS and Quality of Living scales

Physical and neuro-cognitive evaluations

Intervention Type BEHAVIORAL

Physical, neurological and cognitive evaluations.

Safety labs and electrocardiogram

Intervention Type DIAGNOSTIC_TEST

Metabolic panel, CBC and differential, urinalysis, ECG, recreational drugs. CD19+ B-cell count.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Psychosis and cognitive assessments

Administration of MINI, PANSS and Quality of Living scales

Intervention Type BEHAVIORAL

Physical and neuro-cognitive evaluations

Physical, neurological and cognitive evaluations.

Intervention Type BEHAVIORAL

Safety labs and electrocardiogram

Metabolic panel, CBC and differential, urinalysis, ECG, recreational drugs. CD19+ B-cell count.

Intervention Type DIAGNOSTIC_TEST

Ocrelizumab infusion

Two IV infusions of 300 mg of ocrelizumab 2 weeks apart

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Individuals of either sex, 18-35 years of age.
* Having an active psychotic disorder meeting DSM-5 criteria, including a duration of at least six months, for Schizophrenia Spectrum Disorder, as defined by the Mini International Neuropsychiatric Interview (MINI).
* A total PANSS ≥ 60 and a score ≥ 4 on at least 2 of the PANSS positive symptoms.
* Normal academic performance at least until the age of 15 years and absence of psychiatric symptoms before the same age.
* Ability to assent or consent to the performance of the study and participate in testing procedures.

Exclusion Criteria

* The dose of antipsychotic medication (if they are on one) has been changed less than two weeks prior to baseline PANSS testing (Visit 2, see below).
* Patient treated with a medication designed to suppress the immune system, other than standard analgesics or antipyretics, in the six months prior to randomization.
* Vaccinated with a live-attenuated vaccine less than 4 weeks before ocrelizumab infusion or with a non-live vaccine less than 2 weeks before infusion.
* Active infection, or history of or known presence of recurrent or chronic infection (for example, hepatitis B or C, Human Immunodeficiency Virus, syphilis, tuberculosis, PML).
* History of brain tumor, stroke, severe head trauma or multiple sclerosis.
* Active cancer, metabolic encephalopathy, severe cardiovascular or renal disease.
* In the judgment of the PI, psychosis related to substance abuse or metabolic disorders.
* Pregnancy or lactation.
* Requirement for chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study.
* History of or currently active primary or secondary immunodeficiency.
* History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies.
* Contraindications to or intolerance of oral or IV corticosteroids.

Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No